Vertex’s FY2025 Q4 call was dominated by management’s enthusiasm for its future renal franchise, anchored by povitacicept (POVI). Management provided several inflection points, including the completed BLA submission for POVI in H1 2026 and positive Phase 2/3 data for the pipeline. The company provided 8-9% top-line growth guidance for 2026, but the call's primary Alpha signals centered on the potential of the emerging renal portfolio and the impact of its novel mechanisms on treating serious diseases. Total revenue for 2025 was $12.0B (+9% YoY), with Q4 2025 revenue at $3.2B (+10% YoY).
Vertex’s FY2025 Q4 call was dominated by management’s enthusiasm for its future renal franchise, anchored by povitacicept (POVI). Management provided several inflection points, including the completed BLA submission for POVI in H1 2026 and positive Phase 2/3 data for the pipeline. The company provided 8-9% top-line growth guidance for 2026, but the call's primary Alpha signals centered on the potential of the emerging renal portfolio and the impact of its novel mechanisms on treating serious diseases. Total revenue for 2025 was $12.0B (+9% YoY), with Q4 2025 revenue at $3.2B (+10% YoY).
Vertex’s FY2025 Q4 call was dominated by management’s enthusiasm for its future renal franchise, anchored by povitacicept (POVI). Management provided several inflection points, including the completed BLA submission for POVI in H1 2026 and positive Phase 2/3 data for the…
Guidance · revenue to $13.025B
Guidance · revenue to $13.025B
Casgevi maintained momentum with $54M in Q4 revenue and 111 patient initiations, while Journavix generated $27M in Q4 sales.
Vertex is guiding to 8-9% total revenue growth, with management expressing strong confidence in the ramp of non-CF products (Casgevi and Journavix) to contribute $500M+ in 2026, indicating a positive medium-term outlook.
Management expressed confidence in the company's pipeline, commercial execution, and growth trajectory, emphasizing the potential of POVI and the expanding franchise.
“We have not asked us to change anything in the study, and they've given the study clean bills of health as it goes through.”
“We started engaging with the payers in July last year. We've at this point had 74 engagements with multiple payers that cover over 210 million lives.”
“There was a question to one of the thought leaders... they said between 0% and 5%.”
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Op margin | FY2026 | $5.65B–$5.75B | $5.7B | GUIDED |
| Revenue | FY2026 | $12.95B–$13.1B | $13.025B | GUIDED |
| RevenueNON_CF | FY2026 | $0.5B | $0.5B | GUIDED |
Vertex comments on the potential competitor placebo response in IGAN of 0-5% were third-hand (a thought leader), but this supports a thesis that POVI's phase 3 data could show a moat, with a potential significant improvement in proteinuria over placebo if results mimic the 56% reduction seen in Phase 2.